利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1751 条记录 (耗时 0.025 秒)

    DISPOSABLE CARTRIDGE FOR PREPARING A SAMPLE FLUID CONTAINING CELLS FOR ANALYSIS
    43.
    发明申请
    DISPOSABLE CARTRIDGE FOR PREPARING A SAMPLE FLUID CONTAINING CELLS FOR ANALYSIS 审中-公开

    公开(公告)号：US20200240879A1

    公开(公告)日：2020-07-30

    申请号：US16849886

    申请日：2020-04-15

    申请人： PIXCELL MEDICAL TECHNOLOGIES, LTD.

    发明人： Avishay BRANSKY ,  Liron SHLOMO

    IPC分类号： G01N1/20 ,  B01L3/00 ,  G01N33/86

    摘要： A disposable cartridge includes parallel first and second preparation units. An analysis unit may be coupled to both the first preparation unit and the second preparation unit. The analysis unit has a compartment that receives the contents of the at least one pressable chamber of the first preparation unit and the contents of the at least one pressable chamber of the second preparation unit. Upon opening the at least one frangible seal of the first preparation unit, the contents of the at least one pressable chamber of the first preparation unit flows into the compartment of the analysis unit. Further, upon opening the at least one frangible seal of the second preparation unit, the contents of the at least one pressable chamber of the second preparation unit flows into the compartment of the analysis unit.

    In-vitro diagnostic analysis method and system
    45.
    发明授权
    In-vitro diagnostic analysis method and system 有权

    公开(公告)号：US10684297B2

    公开(公告)日：2020-06-16

    申请号：US16274581

    申请日：2019-02-13

    申请人： Roche Diagnostics Operations, Inc.

    发明人： Thomas Meyer ,  Gottlieb Schacher ,  Rolf Sigrist ,  Christian Guzek

    IPC分类号： G01N33/86 ,  G01N35/00 ,  G01N35/02 ,  G01N35/10

    摘要： A method and system for automatic in-vitro diagnostic analysis are described. The method includes adding a first reagent type and a second reagent type to a first test liquid during a first and second cycle times respectively. The addition of the first reagent type to the first test liquid includes parallel addition of a second reagent type to a second test liquid during the first cycle time. The addition of the second reagent type to the first test liquid includes parallel addition of a first reagent type to a third test liquid during the second cycle time, respectively.

    Binding Molecule Activating FXII
    46.
    发明申请
    Binding Molecule Activating FXII 审中-公开

    公开(公告)号：US20200182890A1

    公开(公告)日：2020-06-11

    申请号：US16622064

    申请日：2018-06-28

    申请人： Universitätsklinikum Hamburg-Eppendorf

    发明人： Thomas Renné

    IPC分类号： G01N33/86 ,  C07K16/36 ,  G01N33/68

    摘要： The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.

    Assessment of cardiac health and thrombotic risk in a patient
    48.
    发明授权
    Assessment of cardiac health and thrombotic risk in a patient 有权

    公开(公告)号：US10660942B2

    公开(公告)日：2020-05-26

    申请号：US15700881

    申请日：2017-09-11

    申请人： Paul A. Gurbel

    发明人： Paul A. Gurbel

    IPC分类号： A61K38/36 ,  C12Q1/56 ,  G01N33/86 ,  G01N33/569 ,  A61K31/4365 ,  A61K31/715

    摘要： The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.